Migraine headaches have to be up there on the list of common medical ailments. Nupathe has a patented patch delivery system that will transdermally deliver Sumatriptan to migrane sufferers on FDA approval this coming January. With 31 million migrane sufferers in the U.S. and 8 million of them experiencing nausea in over 50% of their migranes, Nupathe has an excellent opportunity to corner a massive market. Nupathe's product could well become a blockbuster bringing in annual revenues in excess of $1 billion annually. All the math is there to support this. Considering Nupathe currently has a tiny market cap, the shares are truly a gift at this current price which is likely to see appreciation as we near the January 17 decision day for the FDA.